RESTEM, a clinical-stage biotechnology company specializing in innovative cell therapies, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025. Andres Isaias, the company’s Chief Executive Officer, will deliver a corporate overview during a virtual presentation on Wednesday, April 9, 2025, at 11:00 a.m. PT.
The conference, renowned for connecting innovative companies with institutional investors, will feature one-on-one meetings, fireside chats, panels, and networking opportunities. RESTEM plans to showcase its advanced therapeutic approaches, focusing on off-the-shelf cell therapies designed to modulate the immune system.
The company’s scientific portfolio includes two potentially transformative programs: Restem-L, an umbilical cord lining stem cells (ULSCs) program targeting auto-immune diseases, and natural killer cell (NK) therapeutics aimed at addressing senescence and age-associated disorders. These innovative therapies are designed to improve patient outcomes and overall health across a broad range of disabling conditions.
Interested parties can access a live webcast of the presentation through the conference’s digital platform. A replay of the event will be available in the Presentation section of RESTEM’s website following the conference.
The conference represents a critical opportunity for RESTEM to demonstrate its advanced scientific capabilities and potential breakthrough treatments to investors and industry professionals, highlighting the company’s commitment to developing next-generation cell therapies that could significantly impact medical treatment approaches.
This news story relied on a press release distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is RESTEM to Showcase Cell Therapy Innovations at Jones Las Vegas Technology Conference.